US/UK/Canada

Share

Contacts

  • Fluicell AB
    Flöjelbergsgatan 8C Mölndal SE-431 37
    http://www.fluicell.com

    • Links

    Pick a time period -
    Tags ( Active)

    BioStock: Fluicell partners with big pharma for 3-D bioprinting project

    Single-cell technology developers Fluicell have a good reputation in the biomedical research field for its cutting-edge products aimed at maximising R&D capabilities. Fluicell’s 3-D bioprinter Biopixlar has been the main driver for growth thanks to its increased popularity in the industry, and the company announced last week that it has partnered with a big pharma player to use Biopixlar to create bioprinted heart tissue for safety pharmacological studies.Read the full article at biostock.se: https://www.biostock.se/en/2021/09/fluicell-partners-with-big-pharma-for-3-d-bioprinting-project/

    BioStock: 2021 represents beginning of new era for Fluicell

    As we head into the summer, BioStock takes a look at Fluicell’s achievements so far this year. Standing out are the company’s launch of their latest product, Biozone 6, and its dive into the regenerative medicine field through its BioRej Advance programme. BioStock spoke with Fluicell’s CEO Victoire Viannay to get her thoughts on the company’s new direction and what milestones Fluicell has its sights on for the rest of 2021.Read the interview with Victoire Viannay at biostock.se: https://www.biostock.se/en/2021-represents-beginning-of-new-era-for-fluicell/ This is a press release from

    BioStock: Fluicell dives into regenerative medicine field

    Regenerative medicine is an emerging field of research that focuses on the repair, replacement or regeneration of cells, tissues or organs to restore impaired function. The field has the potential to address a sizeable market and have a significant impact on the healthcare industry by reducing the burden of certain diseases or conditions where tissue damage is involved. R&D company Fluicell aims to enter this market by focusing on the development of advanced therapy medicinal products (ATMP) based on transplantable microtissues using the company’s lead product, Biopixlar. BioStock spoke with

    BioStock: The sales team - a key part of Fluicell’s growth

    As an instrument company, sales is a major driver of growth for Fluicell. The year that passed brought many challenges for advancing sales but was also a year where Fluicell greatly expanded its presence on important markets and where the company increased its revenues by 88 per cent despite the pandemic. BioStock spoke with Fluicell’s Chief Sales Officer Matija Rojnik to learn more about the current situation at the company, its strategy for further increasing sales, as well as the importance of having a strong sales team.Read the full interview with Matija Rojnik at biostock.se: https:/

    BioStock: Fluicell launches Biozone 6

    When it comes to single-cell technology for research and development, Swedish Fluicell are considered pioneers in the field, offering a wide range of products based on the properties of microfluidics, which enable manipulation of individual cells in a lab environment with high precision. This week, the company launched its latest product, Biozone 6, a new concept within the field that brings versatility to high-resolution single-cell pharmacology applications.Read the full article at biostock.se: https://www.biostock.se/2021/03/fluicell-lanserar-biozone-6/   This is a press release

    BioStock: 2020 - a year of growth and expansion for Fluicell

    Fluicell began 2020 with the first sale of its then new product, Biopixlar; by the end of the year, the single cell pioneers were able to announce a fourth product based on microfluidic technology. In between, Fluicell has expanded as a company, both in terms of services and in terms of distribution partnerships, and sales of its R&D products have kept strong. BioStock spoke with CEO Victoire Viannay to get her view of the progress made during 2020 and what to expect from the company during 2021.Read the full interview with Victoire Viannay at biostock.se: https://www.biostock.se/en/2020-

    BioStock: Fluicell harnessing microfluidics to spearhead the Biomedical field

    Despite being a small company, Fluicell has already positioned itself as a pioneer in the field of single-cell investigations by developing innovative technologies. To reach such heights, the company’s products are based on advanced microfluidic technology, allowing for the precise control of fluids within a biomedical research setting. To learn more about this technology and how Fluicell has leveraged it in its product development, BioStock reached out to the company’s co-founder and CTO Gavin Jeffries.Read the full interview with Gavin Jeffries at biostock.se: https://www.biostock.se/

    BioStock: Fluicell makes its mark in neuroscience field

    Neurodegenerative diseases are a rapidly growing concern with an increasingly aging population. Decades of research have made it possible to generate neuronal cell cultures in a lab to study their behaviour in disease or injury models or for drug testing. However, these man-made cells lack the complexity of neural tissue to appropriately replicate natural behaviour inside the human body. Gel-free bioprinting has the capacity to address this issue, and Biopixar, Fluicell’s 3-D bioprinter, has shown that direct printing of neurons is possible, which is an important step to create better

    BioStock: Fluicell secures SEK 4 million in directed share issue

    Earlier in the month, Fluicell announced raising 4 MSEK through a directed share issue to strengthen the company’s cash position in order to expand its sales operations. The capital raise comes on the heels of a warrant exercise from June, which brought in 26 MSEK before issue costs. All in all, the Swedish biotech company is well set to continue fulfilling its ambitions of helping researchers in the bio and pharma sectors reach new heights.Read the full article at biostock.se: https://www.biostock.se/en/fluicell-secures-sek-4-million-in-directed-share-issue/ This is a press release

    BioStock: Fluicell answers call for new experimental models

    Animal models are an essential part of R&D within the life science sector in general, and in drug discovery in particular. However, as calls grow for a decrease in the exploitation of animals for medical research, new research tools are being developed to decrease the need for animal experimentation. At the forefront of this endeavour we find the innovative Swedish biotech company Fluicell.Read the full article at biostock.se: https://www.biostock.se/en/fluicell-answers-call-for-new-experimental-models/ This is a press release from BioStock - Connecting Innovation & Capital. https://

    BioStock: Fluicell’s CRO services diversify revenue opportunities

    Fluicell’s main objective is to empower researchers in the healthcare sector to push the bounds of science. The life science company manages this not only by offering a range of innovative single-cell research tools, but also by providing CRO services to researchers aiming for new drug discoveries. The activities, along with academic partnerships, are strong drivers of Fluicell’s growth.Read the full article at biostock.se: https://www.biostock.se/en/fluicells-cro-services-diversify-revenue-opportunities/ This is a press release from BioStock - Connecting Innovation & Capital. https://

    BioStock: Q1 report signals expansion period for Fluicell

    Fluicell is off to a promising start in 2020. This much was clear in the Q1 report released by the Swedish single-cell technology company two weeks ago. The sales numbers are indicative of a strong first quarter for Fluicell with further expansion on the horizon, mainly thanks to the broad range of innovative products that the company already has on the market and its newly established CRO activities.Read the full article at biostock.se: https://www.biostock.se/en/q1-report-signals-expansion-period-for-fluicell/ This is a press release from BioStock - Connecting Innovation & Capital.

    BioStock: Fluicell – pioneers in single-cell technology

    Single-cell technology is revolutionizing how diseases are studied and is thus considered one of the top innovations in the biomedical field in recent years. Fluicell, a biotech company located in Mölndal, has been leading in the field since 2012 when it came out with its first product, BioPen, a tool designed for single-cell manipulation. BioStock takes a closer look at why single-cell technologies play an essential role for the future of the healthcare sector.Read the full article at biostock.se: https://www.biostock.se/en/fluicell-pioneers-in-single-cell-technology/ This is a press

    BioStock: Fluicell at the forefront of 3D bioprinting

    Drug discovery and development is extremely time-consuming. To facilitate the drug discovery process, biotech companies have set out to develop new tools aimed at helping researchers get better results at lower costs. One example is Fluicell, a Swedish company with a strong product portfolio with the promise of answering that call. We caught up with the company’s CEO, Dr Victoire Viannay, to learn more about their technology.Read the full interview with Fluicell's CEO Victoire Viannay at biostock.se: https://www.biostock.se/en/fluicell-at-the-forefront-of-3d-bioprinting/ This is a

    Fluicell AB has in-licensed the Dynaflow® Resolve secondary ion channel screening platform technology from Cellectricon AB

    Fluicell AB is extremely pleased to announce the signing of a license agreement with Cellectricon AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights. The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The

    FLUICELL RECEIVES A NEW PATENT ACCEPTANCE FOR THE BIOPEN SYSTEM

    Fluicell AB, a pioneering high-tech company in single-cell biology, is extremely delighted to announce the issuance of US Patent No 9,6719,671,366, entitled “Pipettes, methods of use, and methods of stimulating an object of interest”, by the USPTO. This is the third patent issued to Fluicell AB, representing a continued advancement of their innovative BioPen system. This platform facilitates complex cell biology experiments at the single-cell level, at affordable prices. This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell

    FLUICELL RECEIVES GREEN LIGHT WITH A NEW BIOPEN PATENT IN THE USA

    Fluicell AB is extremely pleased to announce the approval from the USPTO, of Patent No. 9,658,240, entitled “Microfluidic device with holding interface, and methods of use”. This is the second patent approved for their transformational BioPen product line, which facilitates complex cell biology experiments at single-cell level, at affordable prices. This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell biology research and discovery tools for the 21st century. For further information, please visit us at fluicell.com 

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe